ClinicalTrials.gg
CompletedNCT04188379ADVANCEUpdated Mar 13, 2025Results posted

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

A Phase 3 interventional study of efgartigimod and Placebo in Primary Immune Thrombocytopenia, sponsored by argenx. Completed at 121 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey — 6 open to participants now, 10 under way, 7 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Turkey.

Enrollment
11th of 18
131 · median 144
Started
2019
the only one that year
Phase 3
13 of 19
4 open now
Registered
4th of 19
by date
Lead sponsor
4 of 19
argenx

Among the 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2019, is one of 13 in phase 3, and was the 4th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

6 of the 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Turkey, or all of them as a file.
02

Study summary

This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.

03

Conditions studied

  • Primary Immune Thrombocytopenia

Keywords

  • immune thrombocytopenia
  • sustained platelet count response
  • bleeding events
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand the requirements of the trial, to provide written (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).
  • Male or female patient aged ≥18 years.
  • Confirmed ITP diagnosis, at least 3 months before randomization and according to the American Society of Hematology Criteria, and no known other etiology for thrombocytopenia.
  • Diagnosis supported by a response to a prior ITP therapy (other than thrombopoietin receptor agonists [TPO-RAs]), in the opinion of the investigator.
  • Mean count of \<30×10E9/L from 2 counts: 1 platelet count collected during the screening period and the predose platelet count on the day of randomization.
  • At the start of the trial, the patient is either on concurrent ITP treatment(s) and has received at least 1 prior therapy for ITP in the past, or the patient is not on treatment for ITP but has received at least 2 prior treatments for ITP. Patients receiving permitted concurrent ITP treatment(s) at baseline, must have been stable in dose and frequency for at least 4 weeks prior to randomization.
  • Women of must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at baseline before trial medication (infusion) can be administered.
  • Women of childbearing potential should use a highly effective or acceptable method of during the trial and for 90 days after the last administration of the IMP.

Exclusion criteria

Exclusion criteria:

  • ITP/thrombocytopenia associated with another condition, eg, lymphoma, chronic lymphocytic leukemia, viral infection, hepatitis, induced or alloimmune thrombocytopenia, or thrombocytopenia associated with myeloid dysplasia.
  • Use of certain medications before the start of the studies (more details in the protocol)
  • Patients who have a history of , including malignant thymoma, or myeloproliferative or lymphoproliferative disorders, unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before screening. Patients with completely excised non-melanoma skin cancer (such as basal cell carcinoma or squamous cell carcinoma) or cervical carcinoma in situ would be permitted at any time.
  • Uncontrolled hypertension, defined as a repeated elevated blood pressure exceeding 160 mmHg (systolic) and/or 100 mmHg (diastolic) despite appropriate treatments.
  • History of any major thrombotic or embolic event within 12 months prior to randomization.
  • History of coagulopathy or hereditary thrombocytopenia or a family history of thrombocytopenia.
  • History of a recent or planned major surgery (that involves major organs eg, brain, heart, lung, liver, bladder, or gastrointestinal tract) within 4 weeks of randomization.
  • Positive serum test at screening for an active viral infection with any of the following conditions: virus (HBV), virus (HCV), (HIV)
  • Clinical evidence of significant unstable or uncontrolled acute or chronic diseases other than ITPdespite appropriate treatments which could put the patient at undue risk.
  • Patients with known medical history of to any of the ingredients of the IMP.
  • Patients who previously participated in a clinical trial with efgartigimod and have received at least 1 administration of the IMP.
  • Pregnant or lactating females. More details in the protocol
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    efgartigimod

    Patient receiving efgartigimod

    Biological: efgartigimod

  • Placebo comparator
    Placebo

    Patients receiving placebo

    Other: Placebo

Interventions

  • Biologicalefgartigimod

    Intravenous infusion of efgartigimod

    Also known as: ARGX-113

  • OtherPlacebo

    Intravenous infusion of placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Chronic ITP With a Sustained Platelet Count Response Defined as Achieving Platelet Counts of at Least 50×10^9/L for at Least 4 of the 6 Visits Between Week 19 and 24 of the Trial.

    Percentage of participants with chronic ITP with a sustained platelet count response was defined as achieving platelet counts of at least 50 × 10\^9/L for at least 4 of the 6 visits between Week 19 and 24 of the study.

    Time frame: From Week 19 up to Week 24

Secondary outcomes

  1. Extent of Disease Control Defined as the Number of Cumulative Weeks Over the Planned 24-week Treatment Period With Platelet Counts of ≥50×10^9/L in the Chronic ITP Population

    Extent of disease control, defined as the cumulative number of weeks over the planned 24-week treatment period with platelet counts of ≥50 × 10\^9/L in the chronic ITP population.

    Time frame: From Week 1 up to Week 24

  2. Percentage of Participants With a Sustained Platelet Count Response for at Least 4 of the 6 Visits Between Week 19 and 24 of the Study

    Percentage of participants in the overall population (chronic and persistent ITP) with a sustained platelet count response, defined as achieving platelet counts of at least 50 × 10\^9/L for at least 4 of the 6 visits between weeks 19 and 24 of the study.

    Time frame: From Week 19 up to Week 24

  3. Incidence and Severity of the WHO-classified Bleeding Events

    Incidence of the World Health Organization (WHO)-classified bleeding events in the overall population. This secondary endpoint used the WHO-classified bleeding scale. Bleeding was the predominant clinical manifestation of ITP and was typically related to platelet count. Accordingly, measuring bleeding was important for monitoring this participant population.

    Time frame: From Week 1 to Week 24

  4. Percentage of Participants in the Overall Population Achieving Platelet Counts of at Least 50×10^9/L for at Least 6 of the 8 Visits Between Week 17 and Week 24

    Percentage of participants in the overall population achieving platelet counts of at least 50 × 10\^9/L for at least 6 of the 8 visits between Week 17 and 24 of the study.

    Time frame: From Week 17 up to Week 24

07

Results

Posted Mar 13, 2025
Limitations and caveats
No limitations reported for the study.

Participant flow

This study was conducted at 71 active sites that enrolled participants in 18 countries. Recruitment started on 09 December 2019.

Participant flow — Overall Study
MilestoneEfgartigimodPlacebo
Started8645
Completed6432
Not completed2213
Withdrew: Withdrawal by subject103
Withdrew: Physician decision01
Withdrew: Adverse event31
Withdrew: Pregnancy10
Withdrew: Lack of efficacy85
Withdrew: Other03

Outcome measures

PrimaryPercentage of Participants With Chronic ITP With a Sustained Platelet Count Response Defined as Achieving Platelet Counts of at Least 50×10^9/L for at Least 4 of the 6 Visits Between Week 19 and 24 of the Trial.

Percentage of participants with chronic ITP with a sustained platelet count response was defined as achieving platelet counts of at least 50 × 10\^9/L for at least 4 of the 6 visits between Week 19 and 24 of the study.

Time frame:
From Week 19 up to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Chronic ITP With a Sustained Platelet Count Response Defined as Achieving Platelet Counts of at Least 50×10^9/L for at Least 4 of the 6 Visits Between Week 19 and 24 of the Trial.
Percentage of participantsEfgartigimodPlacebo
Percentage of Participants With Chronic ITP With a Sustained Platelet Count Response Defined as Achieving Platelet Counts of at Least 50×10^9/L for at Least 4 of the 6 Visits Between Week 19 and 24 of the Trial.21.85.0
Statistical analysis
  • Efgartigimod vs Placebo · Cochran-Mantel-Haenszel · p = 0.0316 · Odds ratio (or): 4.884 · 95% CI 1.007 to 43.591
SecondaryExtent of Disease Control Defined as the Number of Cumulative Weeks Over the Planned 24-week Treatment Period With Platelet Counts of ≥50×10^9/L in the Chronic ITP Population

Extent of disease control, defined as the cumulative number of weeks over the planned 24-week treatment period with platelet counts of ≥50 × 10\^9/L in the chronic ITP population.

Time frame:
From Week 1 up to Week 24
Reported as:
Median · Weeks
Extent of Disease Control Defined as the Number of Cumulative Weeks Over the Planned 24-week Treatment Period With Platelet Counts of ≥50×10^9/L in the Chronic ITP Population
WeeksEfgartigimodPlacebo
Extent of Disease Control Defined as the Number of Cumulative Weeks Over the Planned 24-week Treatment Period With Platelet Counts of ≥50×10^9/L in the Chronic ITP Population2.00 (0.00 to 11.00)0.00 (0.00 to 1.00)
Statistical analysis
  • Efgartigimod vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0009 · Median difference (net): 1.000 · 95% CI 0.000 to 4.000
SecondaryPercentage of Participants With a Sustained Platelet Count Response for at Least 4 of the 6 Visits Between Week 19 and 24 of the Study

Percentage of participants in the overall population (chronic and persistent ITP) with a sustained platelet count response, defined as achieving platelet counts of at least 50 × 10\^9/L for at least 4 of the 6 visits between weeks 19 and 24 of the study.

Time frame:
From Week 19 up to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With a Sustained Platelet Count Response for at Least 4 of the 6 Visits Between Week 19 and 24 of the Study
Percentage of participantsEfgartigimodPlacebo
Percentage of Participants With a Sustained Platelet Count Response for at Least 4 of the 6 Visits Between Week 19 and 24 of the Study25.66.7
Statistical analysis
  • Efgartigimod vs Placebo · Cochran-Mantel-Haenszel · p = 0.0108 · Odds ratio (or): 5.224 · 95% CI 1.268 to 26.268
SecondaryIncidence and Severity of the WHO-classified Bleeding Events

Incidence of the World Health Organization (WHO)-classified bleeding events in the overall population. This secondary endpoint used the WHO-classified bleeding scale. Bleeding was the predominant clinical manifestation of ITP and was typically related to platelet count. Accordingly, measuring bleeding was important for monitoring this participant population.

Time frame:
From Week 1 to Week 24
Reported as:
Median · bleeding events
Incidence and Severity of the WHO-classified Bleeding Events
bleeding eventsEfgartigimodPlacebo
Incidence and Severity of the WHO-classified Bleeding Events4.0 (1.0 to 10.0)5.0 (2.0 to 14.0)
Statistical analysis
  • Efgartigimod vs Placebo · Wald Test · p = 0.8287 · Rate ratio: 0.958 · 95% CI 0.651 to 1.41
SecondaryPercentage of Participants in the Overall Population Achieving Platelet Counts of at Least 50×10^9/L for at Least 6 of the 8 Visits Between Week 17 and Week 24

Percentage of participants in the overall population achieving platelet counts of at least 50 × 10\^9/L for at least 6 of the 8 visits between Week 17 and 24 of the study.

Time frame:
From Week 17 up to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants in the Overall Population Achieving Platelet Counts of at Least 50×10^9/L for at Least 6 of the 8 Visits Between Week 17 and Week 24
Percentage of participantsEfgartigimodPlacebo
Percentage of Participants in the Overall Population Achieving Platelet Counts of at Least 50×10^9/L for at Least 6 of the 8 Visits Between Week 17 and Week 2422.16.7
Statistical analysis
  • Efgartigimod vs Placebo · Cochran-Mantel-Haenszel · p = 0.0265 · Odds ratio (or): 4.354 · 95% CI 1.0480 to 22.865

Adverse events

Collected over Full study duration (31 Weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod0/86 (0%)7/86 (8.1%)80/86 (93%)
Placebo0/45 (0%)7/45 (15.6%)43/45 (95.6%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventEfgartigimodPlacebo
ThrombocytopeniaBlood and lymphatic system disorders2/860/45
Road traffic accidentInjury, poisoning and procedural complications0/861/45
AnaemiaBlood and lymphatic system disorders0/861/45
Immune thrombocytopeniaBlood and lymphatic system disorders0/861/45
Mouth haemorrhageGastrointestinal disorders0/861/45
Acute kidney injuryRenal and urinary disorders0/861/45
HaematuriaRenal and urinary disorders0/861/45
AppendicitisInfections and infestations0/861/45
COVID-19Infections and infestations0/861/45
Chronic myelomonocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/860/45
Most frequent other events
Showing 10 of 21
Most frequent other events
EventEfgartigimodPlacebo
Blood urine presentInvestigations31/8617/45
PetechiaeSkin and subcutaneous tissue disorders13/8612/45
HaematomaVascular disorders8/8611/45
ContusionInjury, poisoning and procedural complications17/866/45
EpistaxisRespiratory, thoracic and mediastinal disorders8/868/45
HeadacheNervous system disorders14/866/45
HaematuriaRenal and urinary disorders14/866/45
Mouth haemorrhageGastrointestinal disorders7/867/45
Gingival bleedingGastrointestinal disorders4/866/45
EcchymosisSkin and subcutaneous tissue disorders5/866/45

Baseline characteristics

Full Analysis Set: All randomized participants.

Age, Categorical
Age, Categorical(Participants)EfgartigimodPlaceboTotal
<=18 years000
Between 18 and 65 years7532107
>=65 years111324
Age, Continuous
Age, Continuous(years)EfgartigimodPlaceboTotal
Mean46.9 ± 16.5551.7 ± 17.9348.6 ± 17.12
Sex: Female, Male
Sex: Female, Male(Participants)EfgartigimodPlaceboTotal
Female472471
Male392160
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EfgartigimodPlaceboTotal
American Indian or Alaska Native000
Asian538
Native Hawaiian or Other Pacific Islander000
Black or African American000
White8041121
More than one race101
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EfgartigimodPlaceboTotal
Hispanic or Latino415
Not Hispanic or Latino7740117
Japanese538
Unknown or Not reported011
08

Study locations

121 sites
  • Investigator Site 0010038
    Tucson, Arizona 85711, United States
  • Investigator Site 0010045
    Washington, District of Columbia 20007, United States
  • Investigator Site 0010034
    Jacksonville, Florida 32204, United States
  • Investigator site 0010037
    Ocala, Florida 34474, United States
  • Investigator Site 0010042
    Iowa City, Iowa 52242, United States
  • Investigator Site 0010046
    Greenville, North Carolina 27834, United States
  • Investigator Site 0010049
    Cleveland, Ohio 44106, United States
  • Investigator Site 0010040
    Columbus, Ohio 44106, United States
  • Investigator Site 0010041
    Philadelphia, Pennsylvania 19104, United States
  • Investigator Site 0430004
    Linz, Austria
  • Investigator Site 0430002
    Vienna, Austria
  • Investigator Site 0430003
    Vienna, Austria
  • Investigator Site 0320012
    Brasschaat, Belgium
  • Investigator Site 0320011
    Brugge, Belgium
  • Investigator Site 0320015
    Leuven, Belgium
  • Investigator Site 0320014
    Turnhout, Belgium
  • Investigator Site 0320020
    Verviers, Belgium
  • Investigator site 0320002
    Yvoir, Belgium
  • Investigator Site 3590001
    Pleven, Bulgaria
  • Investigator Site 3590002
    Sofia, Bulgaria
  • Investigator Site 4200001
    Brno, Czechia
  • Investigator Site 4200008
    Olomouc, Czechia
  • Investigator Site 4200006
    Ostrava, Czechia
  • Investigator Site 4200007
    Praha, Czechia
  • Investigator Site 0330019
    Clermont-Ferrand, France
  • Investigator Site 0330009
    Créteil, France
  • Investigator Site 0330015
    Le Mans, France
  • Investigator Site 0330018
    Montpellier, France
  • Investigator Site 0330008
    Pessac, France
  • Investigator Site 0330016
    Périgueux, France
  • Investigator Site 0330017
    Rouen, France
  • Investigator Site 9950006
    Tbilisi, Georgia
  • Investigator Site 9950007
    Tbilisi, Georgia
  • Investigator Site 9950008
    Tbilisi, Georgia
  • Investigator Site 9950009
    Tbilisi, Georgia
  • Investigator Site 9950011
    Tbilisi, Georgia
  • Investigator Site 9950012
    Tbilisi, Georgia
  • Investigator Site 0490010
    Düsseldorf, Germany
  • Investigator Site 0490008
    Essen, Germany
  • Investigator Site 0490012
    Gießen, Germany
  • Investigator Site 0360004
    Budapest, Hungary
  • Investigator Site 0360006
    Debrecen, Hungary
  • Investigator Site 0360015
    Győr, Hungary
  • Investigator site 0360010
    Nyiregyhaza, Hungary
  • Investigator Site 0360014
    Szombathely, Hungary
  • Investigator Site 0390012
    Campobasso, Italy
  • Investigator Site 0390014
    Milan, Italy
  • Investigator Site 0390020
    Monza, Italy
  • Investigator Site 0390015
    Novara, Italy
  • Investigator Site 0390010
    Ravenna, Italy
  • Investigator Site 0390011
    Reggio Calabria, Italy
  • Investigator Site 0390018
    Reggio Emilia, Italy
  • Investigator Site 0390019
    Rimini, Italy
  • Investigator Site 0390021
    Roma, Italy
  • Investigator Site 0390009
    Siena, Italy
  • Investigator Site 0390017
    Torino, Italy
  • Investigator Site 0390016
    Trieste, Italy
  • Investigator Site 0810024
    Bunkyō-Ku, Japan
  • Investigator Site 0810015
    Hirakata, Japan
  • Investigator Site 0810010
    Hiroshima, Japan
  • Investigator site 0810017
    Iruma, Japan
  • Investigator site 0810011
    Isehara, Japan
  • Investigator Site 0810022
    Kashiwa, Japan
  • Investigator site 0810018
    Maebashi, Japan
  • Investigator site 0810020
    Minato-Ku, Japan
  • Investigator Site 0810021
    Niigata, Japan
  • Investigator site 0810014
    Sapporo, Japan
  • Investigator site 0810016
    Shibukawa, Japan
  • Investigator Site 0810023
    Shimotsuke, Japan
  • Investigator Site 0810025
    Shinjuku-Ku, Japan
  • Investigator site 0310006
    Den Haag, Netherlands
  • Investigator Site 0310005
    Rotterdam, Netherlands
  • Investigator Site 0310007
    Rotterdam, Netherlands
  • Investigator Site 0480030
    Białystok, Poland
  • Investigator Site 0480015
    Brzozów, Poland
  • Investigator Site 0480010
    Bydgoszcz, Poland
  • Investigator Site 0480013
    Chorzów, Poland
  • Investigator Site 0480012
    Gdańsk, Poland
  • Investigator Site 0480008
    Katowice, Poland
  • Investigator Site 0480011
    Lodz, Poland
  • Investigator Site 0480014
    Lublin, Poland
  • Investigator site 0480026
    Nowy Sącz, Poland
  • Investigator Site 0480016
    Wrocław, Poland
  • Investigator site 0070006
    Kaluga, Russian Federation
  • Investigator Site 0070007
    Petrozavodsk, Russian Federation
  • Investigator Site 0070013
    Rostov-on-Don, Russian Federation
  • Investigator Site 0070015
    Syktyvkar, Russian Federation
  • Investigator Site 0070012
    Tula, Russian Federation
  • Investigator site 0070010
    Ufa, Russian Federation
  • Investigator Site 0340006
    Barcelona, Spain
  • Investigator Site 0340007
    Barcelona, Spain
  • Investigator Site 0340030
    Burgos, Spain
  • Investigator Site 0340009
    Madrid, Spain
  • Investigator Site 0340014
    Madrid, Spain
  • Investigator Site 0340015
    Madrid, Spain
  • Investigator site 0340012
    Palma De Mallorca, Spain
  • Investigator Site 0340013
    Sevilla, Spain
  • Investigator Site 0340004
    Valencia, Spain
  • Investigator Site 0340011
    Valencia, Spain
  • Investigator Site 0900002
    Adana, Turkey

Showing the first 100 of 121 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Feb 2022, 25 months.

Results were first posted in Mar 2025, 3 years 1 month after primary completion. A results delay was requested in Feb 2023.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 25 months is close to that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2019
First posted
Dec 5, 2019
StartActual
Dec 16, 2019
Primary completionActual
Feb 3, 2022
CompletionActual
Feb 3, 2022
Results delay requested
Feb 2, 2023
Results first posted
Mar 13, 2025
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04188379
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Dec 16, 2019
Primary completion
Feb 3, 2022
Completion
Feb 3, 2022
Results posted
Mar 13, 2025
Last update
Mar 13, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion